317 articles
3SBio long-acting erythropoiesis-stimulating agent
罗赛促红素α (新比澳, SSS06/rESP) is 3SBio's long-acting erythropoiesis-stimulating agent, a high-glycosylated recombinant EPO with a 120-hour half-life, approved by NMPA in March 2026 for anemia of chronic kidney disease in hemodialysis patients, dosed intravenously every two weeks.
5yrGH study
5yrGH (NCT00462475), Effect of 5 Years of GH Replacement on Atherosclerosis, a phase 4 observational study at Federico II University, Naples, led by Annamaria Colao, showing 5 years of GH replacement reduced carotid IMT and insulin-resistance syndrome in men with severe GHD.
Abaloparatide
Abaloparatide (Tymlos, Eladynos), a PTHrP(1-34) analog PTH1-receptor agonist, is an anabolic osteoporosis drug given as 80 mcg daily subcutaneous injection, FDA-approved 2017, EU 2022.
Abarelix
Abarelix (Plenaxis), a GnRH antagonist by Praecis, gave injection-based testosterone suppression without surge for advanced prostate cancer; FDA approved November 25, 2003 with restricted distribution, withdrawn from the US market after anaphylaxis risk.
ABP-671
ABP-671 (lingdolinurad) is an oral URAT1 inhibitor by Atom Therapeutics for gout and hyperuricemia, showing superior serum uric acid lowering versus febuxostat in Phase 2b and entering Phase 3 in China and globally.
Acetohexamide
Acetohexamide (Dymelor, Cyclamide) is a first-generation, intermediate-acting oral sulfonylurea for type 2 diabetes, metabolized to the more potent active metabolite hydroxyhexamide; discontinued in the US market.
Acipimox
Acipimox (Olbetam), a synthetic nicotinic acid derivative, inhibits adipose lipolysis to lower free fatty acids and triglycerides; EU use is restricted to adjunctive or alternative treatment of hypertriglyceridaemia.
Albiglutide
Albiglutide (Eperzan, Tanzeum) is a once-weekly GLP-1 receptor agonist, a GLP-1 dimer fused to albumin, for type 2 diabetes; approved 2014, shown superior to placebo for cardiovascular events, withdrawn commercially in 2018.
Aleglitazar
Aleglitazar: Roche's dual PPARα/γ agonist (C24H23NO5S) for type 2 diabetes; improved HbA1c and lipids but AleCardio phase III (7,226 patients) stopped July 2013 for futility and renal, bleeding, heart-failure signals.
Aleniglipron
Aleniglipron (GSBR-1290) is Structure Therapeutics' oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist for obesity; phase 2 ACCESS trials showed up to 16.3% placebo-adjusted weight loss at 44 weeks, with phase 3 planned for 2026.
Allopurinol
Allopurinol is an oral xanthine oxidase inhibitor, also called Zyloprim, approved in 1966 for gout, cancer-therapy hyperuricemia, and hyperuricosuric kidney stones; dosing is titrated to urate targets with HLA-B*58:01 testing advised in some groups.
Alogliptin
Alogliptin (Nesina, Vipidia; code SYR-322) is Takeda's once-daily DPP-4 inhibitor for type 2 diabetes, FDA-approved January 25, 2013, dosed 25 mg daily with renal adjustments, with cardiovascular safety shown in the EXAMINE trial.
Anacetrapib
Anacetrapib (MK-0859) is an investigational Merck CETP inhibitor that lowers LDL and raises HDL cholesterol, reduced cardiovascular events in the 30,449-patient REVEAL trial, but accumulates in adipose tissue and was never submitted for approval.
Anagestone acetate
Anagestone acetate (Anatropin, ORF-1658), a synthetic pregnane progestin introduced in 1968 in a combined oral contraceptive with mestranol, withdrawn worldwide by 1970 after beagle dog mammary tumor findings.
Anagliptin
Anagliptin (Beskoa, Suiny) is a highly selective DPP-4 inhibitor approved and launched in Japan in 2012 for type 2 diabetes, dosed 200 mg twice daily, with LDL-C-lowering effects and few adverse events.
Androgen therapy
Androgen therapy is the medical administration of androgen hormones, most often testosterone, to restore normal levels and relieve symptoms of androgen deficiency, chiefly male hypogonadism.
Antenatal corticosteroid therapy
Antenatal corticosteroid therapy gives betamethasone or dexamethasone to pregnant women at high risk of preterm delivery to speed fetal lung maturation, cutting neonatal death and respiratory disease by roughly 30 to 50 percent.
AP306
AP306 (EOS-789) is an oral first-in-class pan phosphate transporter inhibitor blocking NaPi-IIb, PiT-1, and PiT-2, developed by R1 Therapeutics and Alebund for hyperphosphatemia in dialysis patients, now in a global Phase 2b trial.
Arzoxifene
Arzoxifene (LY353381), an Eli Lilly benzothiophene SERM related to raloxifene, was tested for breast cancer and osteoporosis; inferior to tamoxifen in phase III and never marketed.
ASC30
ASC30 is Ascletis' investigational small-molecule GLP-1R biased agonist (no beta-arrestin recruitment) for obesity and diabetes, dosed once daily orally and once monthly subcutaneously; Phase II showed 7.7% placebo-adjusted weight loss at 13 weeks.
Atamestane
Atamestane (SH-489, 1-methyl-1,4-androstadiene-3,17-dione) is an investigational steroidal aromatase inhibitor developed by Schering AG; BPH trials showed no benefit over placebo and its phase III breast cancer trial matched but did not beat letrozole.
Atorvastatin
Atorvastatin, sold originally as Lipitor, is a statin medicine that blocks cholesterol synthesis, lowering LDL cholesterol by up to about 50% and preventing heart attacks and strokes.
Atosiban
Atosiban (Tractocile) is a synthetic oxytocin receptor antagonist peptide used as a tocolytic to delay preterm birth at 24 to 33 weeks gestation; given by IV bolus plus 48-hour infusion, it matches beta-agonists and nifedipine in efficacy with fewer maternal side effects.
Avexitide
Avexitide (exendin 9-39) is an investigational first-in-class GLP-1 receptor antagonist by Amylyx for post-bariatric hypoglycemia; Phase 3 LUCIDITY met its endpoint with a 55% reduction in Level 2/3 hypoglycemic events, NDA planned by end of 2026.
AYUSH-82 (marketed as IME-9)
AYUSH-82, sold as IME-9, Right Sugar, Diavit 82, and DB6, is a CCRAS-developed polyherbal Ayurvedic anti-diabetic formulation of mango, bitter melon, jamun seeds, and Gymnema leaves, commercialized via NRDC since 2016.
AYUSH-D
AYUSH-D is a coded polyherbal Ayurvedic antidiabetic formulation developed by India's CCRAS from local health tradition leads, patented in 2017, and tested in completed Phase II placebo-controlled trials as add-on therapy to metformin in type 2 diabetes and prediabetes.
Balaglitazone
Balaglitazone (DRF-2593) is a thiazolidinedione PPARγ partial agonist developed by Dr. Reddy's and Novo Nordisk for type 2 diabetes; its phase III BALLET trial showed HbA1c lowering with less edema than pioglitazone, but it was never marketed.
Bazedoxifene
Bazedoxifene (Conbriza, Duavee) is a third-generation SERM approved in the EU and Japan for postmenopausal osteoporosis, reducing vertebral fractures about 35-40% over 5 years; in the US it is sold only with conjugated estrogens.
Beclobrate
Beclobrate (CAS 55937-99-0), a clofibrate-analog fibric acid derivative antihyperlipidemic introduced in 1985; lowered LDL-C and triglycerides at 100 mg once daily; withdrawn in Switzerland in 1990 after fatal hepatitis reports.
Beinaglutide
Beinaglutide (贝那鲁肽, Yishengtai) is a short-acting GLP-1 receptor agonist, recombinant human GLP-1(7-36) with 100% human sequence, developed by Shanghai Benemae and approved in China in December 2016 for type 2 diabetes and weight management.